The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.
BEDMINSTER, N.J. and DUBLIN, Ireland, June 04, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Gwen Fisher has joined the company in a newly created role as vice president of Corporate
BEDMINSTER, N.J., and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
- PDUFA date assigned is September 28, 2019, four months sooner than expected - Vascepa , assuming approval, will be first drug indicated to reduce residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, as studied in the landmark
Vascepa’s REDUCE-IT Trial Impact on Clinical Practice an Important Highlight BEDMINSTER, N.J. and DUBLIN, Ireland, May 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Vascepa® (icosapent
Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, May 01, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on
BEDMINSTER, N.J., and DUBLIN, Ireland, April 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (TSX:HLS), has filed a New Drug Submission (“NDS”)
BEDMINSTER, N.J. and DUBLIN, Ireland, April 24, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's
BEDMINSTER, N.J., and DUBLIN, Ireland, March 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (TSX: HLS ), has received formal confirmation
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that, as planned, it submitted a supplemental new drug application (sNDA) to the U.S.